These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 35931943)

  • 1. Evaluation of Safety and Clinically Relevant Drug-Drug Interactions with Tucatinib in Healthy Volunteers.
    Topletz-Erickson A; Lee A; Rustia EL; Sun H; Mayor JG; Abdulrasool LI; Walker L; Endres CJ
    Clin Pharmacokinet; 2022 Oct; 61(10):1417-1426. PubMed ID: 35931943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Creation of Novel Sensitive Probe Substrate and Moderate Inhibitor Models for a Comprehensive Prediction of CYP2C8 Interactions for Tucatinib.
    Templeton IE; Rowland-Yeo K; Jones HM; Endres CJ; Topletz-Erickson AR; Sun H; Lee AJ
    Clin Pharmacol Ther; 2024 Feb; 115(2):299-308. PubMed ID: 37971208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers.
    Tugnait M; Gupta N; Hanley MJ; Sonnichsen D; Kerstein D; Dorer DJ; Venkatakrishnan K; Narasimhan N
    Clin Pharmacol Drug Dev; 2020 Feb; 9(2):214-223. PubMed ID: 31287236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and Drug-Drug Interaction of Ocedurenone (KBP-5074) in vitro and in vivo.
    Wang P; Liu J; Tan X; Yang F; McCabe J; Zhang J
    Eur J Drug Metab Pharmacokinet; 2023 Jul; 48(4):397-410. PubMed ID: 37357226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK.
    Nguyen L; Holland J; Miles D; Engel C; Benrimoh N; O'Reilly T; Lacy S
    J Clin Pharmacol; 2015 Sep; 55(9):1012-23. PubMed ID: 25854986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of gemfibrozil and rifampicin on the pharmacokinetics of selexipag and its active metabolite in healthy subjects.
    Bruderer S; Petersen-Sylla M; Boehler M; Remeňová T; Halabi A; Dingemanse J
    Br J Clin Pharmacol; 2017 Dec; 83(12):2778-2788. PubMed ID: 28715853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the drug-drug interaction potential of brigatinib using a physiologically-based pharmacokinetic modeling approach.
    Hanley MJ; Yeo KR; Tugnait M; Iwasaki S; Narasimhan N; Zhang P; Venkatakrishnan K; Gupta N
    CPT Pharmacometrics Syst Pharmacol; 2024 Apr; 13(4):624-637. PubMed ID: 38288787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Drug-Drug Interaction Studies to Evaluate the Effects of a P-Glycoprotein Inhibitor, CYP3A Inhibitors, and a CYP3A Inducer on the Pharmacokinetics of Naldemedine in Healthy Subjects.
    Fukumura K; Kawaguchi N; Ishibashi T; Kubota R; Tada Y; Ogura E
    Clin Drug Investig; 2020 Jun; 40(6):529-540. PubMed ID: 32323104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the Potential for Cytochrome P450 and Transporter-Mediated Drug-Drug Interactions for Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor (FXR) Agonist.
    Younis I; Weber E; Nelson C; Kirby BJ; Shen G; Xiao D; Watkins TR; Othman AA
    Clin Pharmacokinet; 2023 Apr; 62(4):609-621. PubMed ID: 36906733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects.
    Zahir H; Greenberg J; Shuster D; Hsu C; Watanabe K; LaCreta F
    Clin Pharmacokinet; 2022 Nov; 61(11):1623-1639. PubMed ID: 36264536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Open-Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants.
    Li J; Rockich K; Yuska B; Zhou G; Epstein N; Punwani N; Chen X; Yeleswaram S
    J Clin Pharmacol; 2020 Nov; 60(11):1519-1526. PubMed ID: 32515832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin.
    Kajosaari LI; Laitila J; Neuvonen PJ; Backman JT
    Basic Clin Pharmacol Toxicol; 2005 Oct; 97(4):249-56. PubMed ID: 16176562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1 study to evaluate the effects of rifampin or itraconazole on the pharmacokinetics of limertinib (ASK120067), a novel mutant-selective inhibitor of the epidermal growth factor receptor in healthy Chinese subjects.
    Cao B; Huang L; Liu M; Lin H; Ma T; Zhao Y; Geng Y; Yang Y; Guo H; Li J
    Expert Opin Drug Metab Toxicol; 2023 Sep; 19(9):653-664. PubMed ID: 37811634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes.
    Marzolini C; Rajoli R; Battegay M; Elzi L; Back D; Siccardi M
    Clin Pharmacokinet; 2017 Apr; 56(4):409-420. PubMed ID: 27599706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the Cytochrome P450 3A and P-glycoprotein Drug-Drug Interaction Potential of Futibatinib.
    Yamamiya I; Hunt A; Takenaka T; Sonnichsen D; Mina M; He Y; Benhadji KA; Gao L
    Clin Pharmacol Drug Dev; 2023 Oct; 12(10):966-978. PubMed ID: 37132707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites Alone and in Combination with Gemfibrozil, Itraconazole, or Rifampin in Healthy Subjects: A Randomized, Parallel-Group, Open-Label Study.
    Tran JQ; Zhang P; Ghosh A; Liu L; Syto M; Wang X; Palmisano M
    Adv Ther; 2020 Oct; 37(10):4381-4395. PubMed ID: 32857315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of SHR0302 on the pharmacokinetics of CYP3A4, CYP2C8, CYP2C9 and CYP2C19 probe substrates in healthy volunteers: A cocktail analysis.
    Fu M; Luo L; Feng S; Lin H; Lu Z; Gu F; Fan Y; Wu B; Huang J; Shen K
    Br J Clin Pharmacol; 2023 Dec; 89(12):3659-3668. PubMed ID: 37464978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elimination of tucatinib, a small molecule kinase inhibitor of HER2, is primarily governed by CYP2C8 enantioselective oxidation of gem-dimethyl.
    Sun H; Cardinal KA; Wienkers L; Chin A; Kumar V; Neace C; Henderson C; Endres CJ; Topletz-Erickson A; Regal K; Vo A; Alley SC; Lee AJ
    Cancer Chemother Pharmacol; 2022 Jun; 89(6):737-750. PubMed ID: 35435471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An In Vitro and In Vivo Evaluation of the Effect of Relacorilant on the Activity of Cytochrome P450 Drug Metabolizing Enzymes.
    Custodio JM; Donaldson KM; Hunt HJ
    J Clin Pharmacol; 2021 Feb; 61(2):244-253. PubMed ID: 32869328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An open-label study to explore the optimal design of CYP3A drug-drug interaction clinical trials in healthy Chinese people.
    Chen J; Li J; Wu J; Song Y; Li L; Zhang J; Dong R
    Pharmacol Res Perspect; 2024 Aug; 12(4):e1252. PubMed ID: 39073244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.